Almonertinib vs Limertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Almonertinib

Marketed by Hansoh Pharmaceutical Group and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04500717 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT04841811 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.): ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). (met)

Result source: NCT04500717

Limertinib

Marketed by Jiangsu Aosaikang Pharmaceutical and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Reliable signal

NCT04143607 · Phase 3 · status unknown

The trial randomized 337 patients to limertinib or an active comparator (gefitinib) with full triple-blinding (patient, investigator, and outcomes assessor masked) using matching placebos, which minimizes bias. The primary endpoint, progression-free survival, is a hard clinical measure, and it was met with a large, clinically meaningful improvement in median PFS (20.7 vs 9.7 months), supporting a strong evidence grade.

Next expected readout: December 2026 · NCT06982924 (registry estimate)

Reported efficacy

Median Progression Free Survival (PFS) (CT or MRI at screening and every 2 Cycles until disease progression,date of death or withdrawal from study,whichever came first, assessed up to approximately 2 years): NCT04143607 (limertinib/ASK120067 vs gefitinib first-line trial), primary endpoint median PFS: limertinib 20.7 months vs gefitinib 9.7 months; HR 0.44 (met)

Result source: NCT04143607

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlmonertinibLimertinib
PFS, median—Trial running · NCT06417008—Trial running · NCT07109531
OS, median—Trial running · NCT06417008—Trial running · NCT07109531
ORR—Trial running · NCT06417008—Trial running · NCT07109531
Duration of response, median—Trial running · NCT06417008—Trial running · NCT07109531

PFS, median

Almonertinib
—Trial running · NCT06417008
Limertinib
—Trial running · NCT07109531

OS, median

Almonertinib
—Trial running · NCT06417008
Limertinib
—Trial running · NCT07109531

ORR

Almonertinib
—Trial running · NCT06417008
Limertinib
—Trial running · NCT07109531

Duration of response, median

Almonertinib
—Trial running · NCT06417008
Limertinib
—Trial running · NCT07109531
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Almonertinib
ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). NCT04500717 · Phase 3 · design grade: moderate · publication or press release
Limertinib
NCT04143607 (limertinib/ASK120067 vs gefitinib first-line trial), primary endpoint median PFS: limertinib 20.7 months vs gefitinib 9.7 months; HR 0.44 NCT04143607 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almonertinib's landscape · Limertinib's landscape